Rubric Capital Management (New York)’s Adaptive Biotechnologies ADPT Stock Holding History

Rubric Capital Management (New York)’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,256,847	Closed	-$72.9M	–	73
2025 Q2	$72.9M	Sell	6,256,847 -6,861,004	-52%	-$62.3M	1.1%	26
2025 Q1	$97.5M	Sell	13,117,851 -1,482,149	-10%	-$11.4M	1.75%	16
2024 Q4	$87.5M	Buy	14,600,000 +200,000	+1%	+$1.1M	1.12%	17
2024 Q3	$73.7M	Buy	14,400,000 +400,000	+3%	+$1.74M	1.2%	19
2024 Q2	$50.7M	Buy	14,000,000 +3,500,000	+33%	+$11.1M	1.33%	30
2024 Q1	$33.7M	Buy	10,500,000 +7,637,271	+267%	+$29.6M	1%	35
2023 Q4	$14M	Buy	+2,862,729	New	+$13.1M	0.29%	44

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AAP

Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rubric Capital Management (New York)'s ADPT Position: Q3 2025 in Review

Rubric Capital Management (New York) sold out of Adaptive Biotechnologies (ADPT) in Q3 2025, closing a stake of 6,256,847 shares — an estimated $72.9M sold.

Rubric Capital Management (New York) first reported a position in ADPT in Q4 2023 and held it in 7 quarters. The position peaked at $97.5M in Q1 2025. 271 funds tracked by Wall St. Rank hold ADPT as of Q3 2025.

Rubric Capital Management (New York) reported no remaining Adaptive Biotechnologies position as of Q3 2025 after selling out during the quarter.
Rubric Capital Management (New York) sold 6,256,847 Adaptive Biotechnologies shares in Q3 2025, an estimated $72.9M.
Rubric Capital Management (New York) first reported a position in Adaptive Biotechnologies in Q4 2023 and held it in 7 quarters.
Rubric Capital Management (New York)'s Adaptive Biotechnologies position peaked at $97.5M in Q1 2025.
271 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2025.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2025, filed 14 Nov 2025.